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Abstract  51 
Introduction: 52 
The study’s main aim was to evaluate the relationship between the performance of predictive 53 
models for differential diagnoses of ovarian tumors and levels of diagnostic confidence in 54 
subjective ultrasonographic assessment (SA). The second aim was to identify the parameters 55 
that differentiate between malignant and benign tumors among tumors initially diagnosed as 56 
uncertain in SA. 57 
Material and methods 58 
The study included 250 (55%) benign ovarian masses and 201 (45%) malignant tumors. In 59 
ultrasonographic ultrasonography, the tumors were divided into six groups: certainly benign 60 
(CB), probably benign (PB), uncertain but benign (UB), uncertain but malignant (UM), 61 
probably malignant (PM) and certainly malignant (CM). The performance of the Risk of 62 
Malignancy Index (RMI), International Ovarian Tumor Analysis (IOTA) ADNEX model, and 63 
IOTA logistic regression model 2 (LR2) were analyzed in subgroups as follows: SA-certain 64 
4 
 
tumors (including CB and CM) vs. SA-probable (PB and PM) vs. SA-uncertain (UB and 65 
UM). 66 
Results 67 
We found a progressive decrease in the performance of all models in association with the 68 
increased uncertainty in SA. The AUC for the RMI, LR2 and ADNEX models decreased 69 
between the SA-certain and SA-uncertain groups for 20%, 28%, and 20% respectively. The 70 
presence of solid parts and a high color score were the discriminatory features between UB 71 
and UM tumors. 72 
Conclusions 73 
Studies are needed that focus on the subgroup of ovarian tumors that are difficult to classify in 74 
SA. In cases of uncertain tumors in SA, the presence of solid components or high color score 75 
should prompt a gynecologic oncology clinic referral. 76 
 77 
























Differential diagnosis of ovarian tumor remains a recurrent problem in gynecological practice. 100 
After diagnosis of an ovarian tumor the clinician must make the decision whether the patient 101 
requires surgical treatment, or she can be managed expectantly. Furthermore, if surgery is 102 
indicated, another issue to be resolved is whether the patient should be operated on in a 103 
specialized gynecological oncology center, or she may undergo treatment in a general 104 
gynecologic unit with a minimally invasive approach. Currently, ultrasonography with 105 
subjective assessment (SA) performed by an experienced sonographer is regarded as the most 106 
precise and specific method for the differential diagnosis of ovarian tumors 1,2. SA is superior 107 
to other diagnostic methods such as RMI or ROMA, which also use the analysis of cancer 108 
serum biomarkers 1,3,4 Additionally, SA conducted by an expert is used when other diagnostic 109 
tests yield inconclusive results 5,6. SA by an experienced sonographer is not only used to 110 
differentiate benign from malignant tumors. Nowadays, with more specific imaging available, 111 
recognition is easier. SA may suggest a very specific diagnosis, for example, beyond simple 112 
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differentiation, it may indicate a borderline ovarian tumor or a secondary ovarian malignancy, 113 
thus an individualized treatment approach may be applied as a result 7–10. However, for many 114 
patients there is limited access to SA by an experienced sonographer because there is a 115 
relatively small number of gynaecological ultrasound specialists. Therefore, multiple 116 
diagnostic and predictive models, based on ultrasonography, clinical variables and cancer 117 
biomarker assessment, have been developed to better facilitate the evaluation and diagnosis of 118 
tumors. The idea behind the development of predictive models for a differential diagnosis of 119 
ovarian tumors was to enable inexperienced sonographers to undertake diagnoses 11,12. In that 120 
context, a physician who is less experienced in gynecologic ultrasound, has at their disposal 121 
another diagnostic tool for differentiating malignant from benign ovarian tumors. Therefore, it 122 
could be said that the relative experience of the sonographer determines whether there is a 123 
need to apply a predictive model. However, every sonographer has at least some experience in 124 
differentiating ovarian tumors in SA. Further, it is true that multiple benign ovarian tumors 125 
(for instance, most endometriosis cysts and dermoids) and evident malignancies (i.e., 126 
advanced ovarian cancers) are easy to recognise, even by beginners. In such situations 127 
predictive models are redundant.   128 
Predictive models for the differential diagnosis of ovarian tumors require prospective 129 
validation before clinical application. Most studies report that internal validation is performed 130 
at the time of the original reports. In general, the studies provide detailed characterizations of 131 
the tumors (the ultrasonographic structure, and histopathological type, etc.); however, data is 132 
sparse about the level of diagnostic confidence in relationship to the SA of the tumor 12–15. 133 
This is of clinical significance, because from a practical point of view, the predictive models 134 
should prove to have been effective when using SA by a non-expert is unequivocal. We 135 
hypothesize that as diagnostic certainty decreases in SA, and therefore, as uncertainty 136 
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increases, the accuracy of the other diagnostic tests also decreases. Thus, the main aim of our 137 
study was to evaluate the diagnostic performance of selected diagnostic models in relation to 138 
the degree of uncertainty in SA.  139 
 140 
Materials and method 141 
Informed consent was obtained from all individual participants included in the study. The 142 
study was approved by the Poznan University of Medical Science Ethics Committee (884/17). 143 
We retrospectively evaluated data collected from the ultrasonographic database of ovarian 144 
tumors in patients who had been referred to our clinics. In matter of the material in the study 145 
that was sourced from the Division of Gynecologic Surgery, of the Poznan University of 146 
Medical Sciences, Poland, the data had been obtained from patients treated for ovarian tumors 147 
between December 2010 and April 2018. The study included 368 consecutive women who 148 
had an ultrasonographic examination due to an ovarian tumor that was performed by either 149 
S.Sz or R.M. The study group included women were referred to S.Sz or R.M. for an 150 
ultrasonography consultation by a less-experienced physician; and others who were evaluated 151 
by S.Sz or R.M. because the women were admitted to the hospital on one of these physician’s 152 
routine duty days. Ultrasonography was performed according to the IOTA criteria for 153 
describing the sonographic morphology of ovarian tumors 16. Only patients with CA125 data 154 
available were enrolled. There were no specific exclusion criteria, and the only inclusion 155 
criterion was the patient’s need for surgery due to an ovarian tumor.  156 
Ultrasonography was performed one to three days before surgery. The tumors were evaluated 157 
using Aloka Alpha 10 with a 3.75 – 7.5 MHz endovaginal probe and Aloka 3500 with a 7.5 158 
MHz endovaginal probe (Hitach Aloka, Tokyo, Japan). A transabdominal probe was used in 159 
cases of large tumors. In cases of bilateral ovarian tumors, the data of the tumor with the more 160 
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complex morphology were collected. If the tumors had similar morphologies, the data of the 161 
largest one was selected. The tumors were assessed by either R.M. or S.Sz. R.M. has over 16 162 
years’ experience in gynecological ultrasonography, having performed approximately 800 163 
examinations per year. S.Sz. has 12 years’ experience in gynecological ultrasonography and 164 
in the past two years performed 300 examinations each year, and prior to that, 1000 165 
examinations per year. Both R.M. and S.Sz. conduct clinical studies in the field of 166 
gynecological ultrasonography and teach in numerous courses and give lectures on the field of 167 
ultrasound examinations. However, despite their experience, gynecological ultrasonography is 168 
not the main field of expertise of either S.Sz or R.M., thus, applying the European Federation 169 
of Societies for Ultrasound in Medicine and Biology (EFSUMB) criteria, these sonographers 170 
classify themselves as level 2 examiners. 171 
We also included data collected from June 2016 to September 2017 at the Department of 172 
Gynecologic Oncology, Gdynia Oncology Center, of the Pomeranian Hospitals, Gdynia, 173 
Poland. The study included 83 patients with ovarian tumors who had undergone consecutive 174 
preoperative ultrasonographic examination performed by M.S. All examinations were 175 
performed 1 to 3 days before surgery using the standards and terminology proposed by the 176 
IOTA group 16. Similarly, CA125 serum levels were evaluated 1 to 3 days prior to surgery. 177 
The patients underwent transvaginal or transrectal ultrasound using a Philips HD15 178 
Ultrasound System with Philips C8-4v Endovaginal Probe, 4-8 MHz and Philips V6-2 179 
broadband convex transducer, 6-2 MHz (Philips Healthcare, Koninklijke, The Netherlands). 180 
M.S. has over 20 years of experience in gynecological ultrasonography. He is the author of 181 
numerous studies concerning differential diagnosis of ovarian tumors. M.S. is a teacher of 182 
gynecological ultrasonography and he is regarded as an expert in this field. However, his 183 
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main field of expertise is gynecologic surgery; thus M.S. classifies himself as level 2 184 
ultrasonography practitioner according to the EFSUMB criteria. 185 
Following each ultrasound examination, the examiners indicated their subjective impression 186 
about the tumor’s character, and using the IOTA rules, classified the masses as: certainly 187 
benign (CB), probably benign (PB), uncertain but benign (UB), uncertain but malignant 188 
(UM), probably malignant (PM) and certainly malignant (CM) 1718. Our study’s analysis was 189 
performed between pairs of certain (SA-certain; including CB+CM tumors), probable (SA-190 
probable; including PB+PM tumors ) and uncertain (SA-uncertain; including UB+UM) 191 
tumors because we believe the corresponding groups are similar to each other with regard to 192 
the degree of diagnostic confidence. Each SA examination was a blind test, as the examiners 193 
were not given access to the predictive model results. 194 
All tumors were surgically removed. the reference standard was the final histopathological 195 
diagnosis obtained for all tumors using the WHO classification 19. Borderline tumors were 196 
classified as malignant tumors. Data collected in the ultrasonographic database was used to 197 
assess the following predictive models according to the methodologies described in the source 198 
literature: risk of malignancy index (RMI) [19], logistic regression model 2 [20], and the 199 
Assessment of Different Neoplasias in the adneXa (ADNEX) [21] developed by the 200 
International Ovarian Tumor Analysis (IOTA). The cut-off for RMI was set as 200 points. In 201 
the case of the ADNEX model and LR2, a greater than 10% risk of a malignant tumor was 202 
considered as an indication of malignancy.   203 
The test results were evaluated using the diagnostic odds ratio (DOR) and the area under the 204 
Receiver Operating Characteristic (ROC) curve (AUC) 20. The sensitivity (SENS), specificity 205 
(SPEC), positive predictive value (PPV), negative predictive value (NPV), and the accuracy 206 
of all tests were also calculated.  207 
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Mathematical and statistical analyses were based on software R version 3.5.1 (2018-07-02) 208 
with libraries pROC v. 1.12.1. For categorical variables, independence between groups was 209 
studied using the Fisher exact test. The DeLong et. al., method was used for the comparison 210 
of AUC between subgroups 21. 211 
The study was conducted in adherence with the 2015 guidelines of the Standards for 212 
Reporting of Diagnostic Accuracy Studies (STARD). The study received no funding.  213 
 214 
Results 215 
The study group included 250 benign ovarian masses (55%) and 201 (45%) malignant tumors. 216 
There were 22 (5%) borderline, 44 (10%) stage one and 126 (%) stage II-IV ovarian 217 
malignancies, and 9 (2%) secondary ovarian malignancies. Two-hundred seventy women 218 
were premenopausal (60%), while 181 (40%) were postmenopausal (postmenopausal being 219 
defined as 1 year after the last period and with no other endocrine disorders; or older than 50 220 
years’ old if they had undergone hysterectomy). Data on each patient’s age, CA125 levels and 221 
tumor ultrasonographic morphology according to the type of tumor are shown in Table 1.  222 
By the end of the study, the group included 72 (16%) certainly benign (CB), 137 (30%) 223 
probably benign (PB), 34 (8%) uncertain but benign (UB), 52 (12%) uncertain but malignant 224 
(UM), 74 (16%) probably malignant (PB) and 82 (18%) certainly malignant (CM) ovarian 225 
tumors. 226 
The results of histopathological examinations are shown in Table 2. 227 
The performance of the diagnostic models and the SA in groups of tumors we analyzed is 228 
presented in Table 3.  229 
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In all the models we studied, we observed lower accuracy, sensitivity, specificity, positive and 230 
negative predictive values, and DORs in the group of SA-uncertain tumors compared with the 231 
results for the SA-certain and SA-probable group.  232 
We found significantly higher AUCs for LR2 in the group of SA-certain tumors than in both 233 
the SA-probable (P = 0.001) and SA-uncertain (P = 0.034) groups of tumors. However, there 234 
were no differences in the AUCs when we compared the LR2 model with the SA-probable 235 
and SA-uncertain groups of tumors (P = 0.549). At the same time, we found significantly 236 
higher AUCs for the ADNEX model in the SA-certain tumors group when compared with the 237 
SA-probable (P = 0.012) and SA-uncertain groups of tumors (P = 0.034). The difference in 238 
the AUCs for the ADNEX model comparing the SA-probable and SA-uncertain groups of 239 
tumors was insignificant (P = 0.635). We found no significant differences in the AUCs for 240 
RMI when its performance was compared between the groups of tumors we studied. The P-241 
values for the comparisons of the AUCs for RMI between the groups studied were as follows: 242 
P = 0.122 for SA-certain vs SA-probable tumors; P=0.108 for SA-certain vs SA-uncertain 243 
tumors, and P = 0.146 for SA-probable vs SA-uncertain tumors. The AUC for RMI, LR2 and 244 
ADNEX decreased between the SA-certain and SA-uncertain tumors by 20%, 28% and 20% 245 
respectively. While, the corresponding decreases of the AUC between the SA-probable and 246 
SA-uncertain tumors was 11%, 6% and 11% respectively. 247 
When all six groups of tumors were taken into consideration, we found statistically significant 248 
differences in the patients’ ages, CA-125 levels and the ultrasonographic features between the 249 
levels of diagnostic confidence pertaining to the groups of tumors classified in SA. Detailed 250 
results are presented in the supplementary Table 1. When we subsequently focused on 251 
differentiating between UB and UM tumors, we found solid parts more frequently in UM than 252 
in UB tumors (P < 0.001). Additionally, UM tumors had a significantly higher median color 253 
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score when compared with UB tumors (4, range 2-4 vs 2, range 1-3; P = 0.008). We found no 254 
significant difference between UB and UM tumors in the other ultrasonographic features that 255 
were analyzed. Furthermore, there were no differences between the groups in terms of the 256 
patients’ ages, the CA-125 levels, or menopausal status. The results of the comparisons 257 
between UB and UM tumors are summarized in Table 4.  258 
 259 
Discussion 260 
Predictive models for the differential diagnosis of ovarian tumors were developed mainly to 261 
facilitate diagnosis when experienced sonographic assessment is unavailable. Thus, in 262 
practice, the diagnostic models should improve decision making. However, in our study we 263 
observed a progressive decrease in the performance of predictive models for the differential 264 
diagnosis of ovarian tumors, along with an increased uncertainty with subjective 265 
ultrasonographic assessment. The reduced quality of performance was observed in all of 266 
predictive models we studied (RMI, LR2 and ADNEX) and presented as declines in the 267 
AUCs, DORs and the sensitivity and specificity of the diagnostic tool. The poor performance 268 
of the models was observed in both the uncertain tumors group, as well as in the group of 269 
probably benign and probably malignant tumors. In the cases of tumors where the observer 270 
had no doubt about the character of the tumor, we found that all of the tumors were classified 271 
correctly by SA and all of the predictive models studied performed at an excellent level. On 272 
the other hand, when the diagnosis was difficult in SA, the performances of the predictive 273 
models was also found to be lower. The results of our study point out important issues about 274 
other studies on predictive models for ovarian tumors and the clinical utility of the models. 275 
Firstly, we consider, when the predictive models are assessed, it seems reasonable to provide 276 
the data about the level of diagnostic confidence in SA for the tumors included. In general, 277 
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other studies on the efficacy of prognostic models provide detailed characteristics of 278 
sonographic features and the clinical data on the women in the studies 22–24. Data about 279 
relative confidence levels of the subjective assessment would provide information about the 280 
clinical difficulties encountered in the diagnosis of the tumors included in the studies, thereby 281 
providing essential information about the conditions under which the predictive model was 282 
validated. Secondly, it would be worthwhile evaluating the true clinical utility of predictive 283 
models for ovarian tumors, because our study shows their performance is weaker in those 284 
situations where they are needed the most.   285 
In recent years, numerous predictive models and tests have been developed for the differential 286 
diagnosis of adnexal masses. From a practical point of view, it would be of clinical interest to 287 
distinguish those models which are useful for differential diagnosis specifically for the group 288 
of adnexal tumors which are difficult to assess. In a study by Valentin et al., the authors of the 289 
large multicenter study reported that 7% of adnexal tumors could not be classified by an 290 
experienced sonographer in SA, as either benign or malignant 17. In our study group, 20% of 291 
the tumors studied constituted the subgroup of tumors that were difficult to diagnose in SA 292 
(UB and UM). This incidence of uncertain tumors, a higher percentage than in the cited study, 293 
may have been a result of the character of the tumors we studied; given that the study group 294 
was of ovarian tumors, most of which were malignant, and which had been referred to the 295 
reference center for gynecological surgery for surgery. Furthermore, significant proportions of 296 
the tumors we studied had been sent to us by other physicians for expert consultation. Finally, 297 
we presume that our experience is at a lower level than the highly experienced experts in the 298 
IOTA group. The diagnostics of difficult tumors in SA remains a persistent problem in 299 
gynecology. In the study by Valentin et al., cited above, the authors developed a logistic 300 
regression model to differentiate the unclassifiable adnexal tumors 17. However, the logistic 301 
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regression model, as well as the RMI and CA125 levels assessment, failed to differentiate 302 
benign from malignant tumors in their subgroup of unclassifiable adnexal tumors 17. In 303 
previous study that we published, we found the evaluation of HE4 levels as a useless 304 
additional test for evaluating uncertain adnexal tumors in SA 25. In our present study we have 305 
found that all the predictive models we studied had similar DORs and AUCs within the 306 
uncertain tumors group. However, due to the limited number of cases in our subgroup of 307 
uncertain tumors, we did not set out to compare the models, but to show the rule of the 308 
decreased performance of the predictive model in conjunction with an increased uncertainty 309 
in SA.  310 
In the study by Valentin et al., borderline tumors, fibromas, and serous and mucinous 311 
cystadenoma/cystadenofibroma were the most common among the unclassifiable masses. 312 
Similarly, those types of tumor were significantly more commonly classified incorrectly as 313 
benign or malignant, when compared with the other tumors in their study 17. The authors 314 
compared the ultrasonographic characteristics of the unclassifiable with the classifiable 315 
adnexal masses. The former group of tumors were found to be larger, more often had a 316 
unilocular-solid, multilocular or multilocular-solid appearance, and more often had an 317 
irregular wall and papillary projections when compared with the latter tumors. The 318 
unclassifiable tumors also had fewer papillary projections, smaller solid components, and 319 
more commonly presented with moderate vascularization (Color score 3). In our study we 320 
preferred to compare the ultrasonographic features of the tumors divided into six sub-321 
categories according to the levels of diagnostic confidence in SA. We found that the group of 322 
tumors categorized as difficult to classify in SA shared intermediate features with those 323 
tumors classified at the two boundaries of diagnostic confidence. That indicates, that the 324 
group of difficult to classify tumors in SA include the features of both malignant and benign 325 
15 
 
tumors, therefore making them difficult to classify both in SA and with predictive models. 326 
Next we focused on differentiating between the UB and UM tumors. Here we found, that the 327 
presence of solid components and high color scores were the discriminatory features between 328 
the UB and UM tumors. However, more than half of the UB tumors were also found to have 329 
solid tumor elements. When considering the color scores, one-third of the UB tumors (35%) 330 
were moderately (score 3) or highly (score 4) vascularized. In the previously cited study by 331 
Valentin et al., the only variable used in their multivariate regression model to calculate the 332 
risk of malignancy among unclassifiable ovarian tumors was the diameter of the largest solid 333 
components 17. However, the logistic regression model they developed performed weakly 334 
when discriminating between malignant and benign ovarian tumors in the subgroup of 335 
unclassified tumors 17. The management of indeterminate ovarian masses remains a persistent 336 
problem in gynecology. The First International Consensus Report on Adnexal Masses 337 
includes a “next steps” proposition when the diagnosis of an indeterminate ovarian tumor is 338 
established. However, in the end, referral to a gynecologic oncologist for surgical evaluation 339 
remains a reasonable option 26. 340 
To the best of our knowledge, this is the first study reporting the relationship between the 341 
degrees of uncertainty in SA with the performance levels of predictive models. The advantage 342 
of our study is that it was conducted in two centers, included a significant number of patient 343 
cases, and involved comprehensive ultrasonographic assessment of the tumors. Additionally, 344 
the performance of the predictive models was analyzed using their sensitivity, specificity, 345 
negative and positive predictive values as well as the AU-ROCs and DORs. However, the 346 
study does have some limitations.  The main limitations of this study include its retrospective 347 
character. Additionally, the proportion of malignant to benign ovarian tumors reported in our 348 
study is a reflection of the proportion that is characteristic of gynecologic oncology clinics, 349 
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and does not therefore reflect the actual incidence ratios of malignant and benign ovarian 350 
tumors. Furthermore, the degree of diagnostic confidence is very subjective and is strictly 351 
related to the relative experience of examiners. We did not perform an analysis of the various 352 
cut-offs and the calibration of analyzed models, because the aim of our study was not to 353 
evaluate their performance, but to show the relationship between the performances of the 354 
various models and the diagnostic confidence in SA.  355 
 356 
Conclusions 357 
Implications for research: 358 
We propose that, because of the significantly weaker diagnostic performance of the diagnostic 359 
models with the tumors in the difficult to classify as benign or malignant group in SA, future 360 
clinical studies should give additional attention to this subgroup of ovarian tumors.  361 
Furthermore, when new predictive models are developed, or, the validation of existing models 362 
is tested, it would be reasonable to include, along with the characteristics of the ovarian 363 
tumors, data concerning the levels of diagnostic confidence in SA.  364 
Implications for practice:  365 
In cases of uncertain tumors in SA, the presence of solid components or abundant tumor 366 
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Table 1. Clinical and ultrasound ovarian tumor characteristics according to the reference 498 















 Median (inter-quartile range) 















90.5 (55-170) 117 (94-152) 100 (51-134) 105 (85-
180) 
Solid part maximal 
diameter 
0 (0-20) 19.5 (12-51) 50 (24-54) 50 (32-74) 50 (45-57) 
Number (%) 
Presence of solid 
parts 
93 (37%) 18 (82%) 39 (89%) 123 (98%) 8 (89%) 
More than 10 
locules 
23 (9%) 7 (32%) 10 (23%) 21 (17%) 1 (11%) 
Acoustic shadows 22 (9%) 1 (5%) 0 (0%) 6 (5%) 0 (0%) 
Ascites 15 (6%) 2 (9%) 10 (23%) 73 (58%) 3 (33%) 
Number of papillary projections N (%) 
0 147 (59%) 6 (27%) 18 (41%) 66 (52%) 5 (56%) 
1 26 (10%) 2 (9%) 3 (7%) 12 (10%) 1 (11%) 
2 27 (11%) 2 (9%) 4 (9%) 6 (5%) 1 (11%) 
3 24 (10%) 4 (18%) 5 (11%) 9 (7%) 1 (11%) 































































adenofibroma 4 (0.9%) 4 (0.9%) 8 (1.8%) 
adult teratoma 30 (6.7%) 5 (1.1%) 35 (7.8%) 
Brenner tumor 12 (2.7%) 10 (2.2%) 22 (4.9%) 
corpus luteum cyst 0 (0.0%) 2 (0.4%) 2 (0.4%) 
endometrioid cyst 4 (0.9%) 4 (0.9%) 8 (1.8%) 
granulosa cell tumor 2 (0.4%) 2  (0.4%) 4 (0.9%) 
hemorrhagic cyst 11 (2.4%) 11 (2.4%) 22(4.9%) 
mucinous cystadenoma 78 (17.3%) 4 (0.9%) 82 (18.2%) 
peduculated leiomyoma 4 (0.9%) 0 (0.0%) 4 (0.9%) 
serous cystadenoma 6 (1.3%) 0 (0.0%) 6 (1.3%) 
simple cyst 5 (1.1%) 4 (0.9%) 9 (2.0%) 
theca cell tumor 3 (0.7%) 3 (0.7%) 6 (1.3%) 
tubo-ovarian abscess 19 (4.2%) 11 (2.4%) 30 (6.7%) 
borderline tumor 3 (0.7%) 1 (0.2%) 4 (0.9%) 
clear cell 
adenocarcinoma 
37 (8.2%) 70 (15.5%) 107 (23.7%) 
endometrioid 
adenocarcinoma 
18 (4.0%) 24 (5.3%) 42 (9.3%) 
mucinous 
adenocarcinoma 
14 (3.1%) 5 (1.1%) 19 (4.2%) 
serous adenocarcinoma 2 (0.4%) 5 (1.1%) 7 (1.6%) 
metastatic ovarian tumor 10 (2.2%) 1 (0.2%) 11 (2.4%) 
undifferentiated 
carcinoma 
8 (1.8%) 15 (3.3%) 23 (5.1%) 














Table 3. The performance of diagnostic models and subjective assessment (SA) within the 568 
subgroups of ovarian tumors analyzed 569 
 570 
 571 
ACC – accuracy; ADNEX - Assessment of Different Neoplasiasin the adneXa (ADNEX) developed by the 572 
IOTA group; AUC - area under the receiver operating characteristic (ROC) curve (AUC); DOR – diagnostic 573 
odds ratio; LR2 - logistic regression model 2 by the International Ovarian Tumor Analysis (IOTA) group; NA – 574 
not available; NPV – negative predictive value; PPV – positive predictive value; RMI – risk of malignancy 575 
index; SA – subjective assessment by an ultrasonographer; SA-certain – refers to ovarian tumors assessed as 576 
certainly malignant or certainly benign in SA; SA-probable – refers to ovarian tumors assessed as probably 577 
malignant or probably benign in SA; SA-uncertain – refers to ovarian tumors assessed as uncertain in SA, and 578 
finally classified as uncertain but malignant, or uncertain but benign; SEN – sensitivity, SPEC – specificity; 95% 579 





















AUC [95% CI] 
SA- certain 
tumors 














LR2 0.927 [0.874 - 
0.972] 




1 [1-1] NA 0.981 [0.945-
0.981] 
Adnex 0.87 [0.802 - 
0.925] 




1 [1-1] NA 1 [1-1] 





































































































































Table 4. The comparison of ultrasonographic features, CA-125 levels and patient 597 
characteristics between the ovarian tumors assessed as uncertain but malignant (UM) and as 598 








N = 34 
 
 
Median (inter-quartile range) p-value 
Age 
 
54.5 (46-60) 42 (34-56) 0.212 
CA-125 146.25 (34-584) 35.46 (18-65) 0.554 
Lesion max diameter 106.5 (69-150) 107.5 (61-189) 0.379 
Solid part max diameter 45 (22-50) 12 (0-34) 0.067 
Presence of solid parts 48 (92%) 19 (56%) < 0.001 
More than 10 locules 10 (19%) 6 (18%) 1 
Acoustic shadows 1 (2%) 2 (6%) 0.559 
Ascites 15 (29%) 4 (12%) 0.07 
Color score 3 (2-4) 2 (1-3) 0.008 
number of papillary 
projections 
Number (%) p-value 
0 19 (22%) 14 (16%) 0.848 
1 5 (6%) 5 (6%) 
2 9 (10%) 6 (7%) 
3 6 (7%) 2 (3%) 
more than 3 13 (15%) 7 (8%) 
Tumor classification  Number (%) p-value 
unilocular 1 (1%) 2 (2%) 0.061 
26 
 
unilocular solid 5 (6%) 9 (10%) 
Multilocular 8 (9%) 5 (6%) 
Multilocular solid 26 (30%) 16 (19%) 
solid 12 (14%) 2 (3%) 
Color score Number (%) p-value 
1 8 (9%) 14 (16%) 0.008 
2 17 (20%) 8 (9%) 
3 4 (5%) 6 (7%) 




Supplementary Table 1. Patient’s age, CA125 levels and ultrasonographic features of the tumors from 1 



































 Median (inter-quartile range) 



































50 (20-64) 45 (22-50) 12 (0-34) 0 (0-20) 0 (0-0) < 0.001 
Presence of 
solid parts 
82 (100%) 69 (93%) 48 (92%) 19 (56%) 48 (35%) 15 
(21%) 
< 0.001 
Color score 3 (2-3) 4 (3-4) 3 (2-4) 2 (1-3) 1 (1-2) 1 (1-1) < 0.001 
 Number (%) 
More than 10 
locules  
7 (9%) 26 (35%) 10 (19%) 6 (18%) 10 (7%) 3 (4%) < 0.001 
Acoustic 
shadows 
4 (5%) 1 (1%) 1 (2%) 2 (6%) 16 (12%) 5 (7%) 0.043 
Ascites 48 (59%) 29 (39%) 15 (29%) 4 (12%) 7 (5%) 0 (0%) < 0.001 
Color score number (%) 




2 19 (4%) 9 (2%) 17 (4%) 8 (2%) 33 (7%) 4 (1%) 
3 29 (6%) 14 (3%) 4 (1%) 6 (1%) 11 (2%) 1 (0%) 
4 18 (4%) 41 (9%) 23 (5%) 6 (1%) 2 (0%) 0 (0%) 
number of papillary projections number (%) 
0 50 (11%) 27 (6%) 19 (4%) 14 (3%) 68 
(15%) 
64 (14%) P < 
0.001) 
1 9 (2%) 7 (2%) 5 (1%) 5 (1%) 12 (3%) 6 (1%) 
2 2 (0%) 4 (1%) 9 (2%) 6 (1%) 18 (4%) 1 (0%) 
2 
 
3 2 (0%) 12 (3%) 6 (1%) 2 (0%) 20 (4%) 1 (0%) 
more than 3 19 (4%) 24 (5%) 13 (3%) 7 (2%) 19 (4%) 0 (0%) 
Type of the tumor number (%) 




31 (7%) 48 (11%) 26 (6%)  16 (4%) 20 (4%) 3 (1%) 
notclassifiable 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0%) 0 (0%) 
solid 31 (7%) 15 (3%) 12 (3%) 2 (0%) 11 (2%) 3 (1%) 
unilocular 0 (0%) 1 (0%) 1 (0%) 2 (0%) 38 (8%) 54 (12%) 
unilocular solid 0 (0%) 2 (0%) 5 (1%) 9 (2%) 42 (9%) 3 (1%) 
 4 
